LXEO vs MKC · $147.7M cap vs P/E 8.4, rev $3.81B
Lexeo Therapeutics, Inc. Common Stock (LXEO) versus McCormick & Company Incorporated (MKC) — a side-by-side from cached financials, not a winner call.
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a biotechnology company listed on US.
McCormick & Company Incorporated (MKC) is a packaged foods company listed on US.
LXEO does not have a complete income-statement cache yet.
Latest reported MKC revenue for 2026-05-31 was $3.81B. Net income was $1.17B. MKC currently screens at market cap $13.56B and trailing P/E 8.4.
LXEO currently screens at market cap $147.7M. MKC currently screens at market cap $13.56B and trailing P/E 8.4.
Not investment advice. Open the LXEO and MKC stock pages for the full models.
Not investment advice.